Identifying immune correlates of protection would make it easier to expand the use of COVID-19 vaccines into children, but the absence of such markers is not necessarily a bar to bridging from adult efficacy data to the pediatric population, a US Food and Drug Administration official said.
Doran Fink, deputy director for clinical review in the FDA’s Division of Vaccines Research and Review, said the agency is...







